Screener / SEC EDGAR /CIK 0001082554 /10-K filed Feb 25, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

UNITED THERAPEUTICS Corp UTHR

Employees
1,400
Headquarters
Silver Spring, MD
CEO
Martine A. Rothblatt
Next results
around Feb 24, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $3.2B through the costs to a net profit of $1.3B · income statement of the 10-K

47% operating margin
Revenue to Gross profit: $2.8BRevenue to Cost of revenue: $384.4MGross profit to Operating profit: $1.5BGross profit to Operating expenses: $1.3BOperating profit to Net profit: $1.1BOperating profit to Tax: $379.2MOther income to Net profit: $221.4MOperating expenses to R&D: $550.0MOperating expenses to SG&A: $755.8M Revenue: $3.2B REVENUE $3.2B +11% Y/Y Gross profit: $2.8B · 88% margin GROSS PROFIT $2.8B 88% margin · +9% Y/Y Cost of revenue: $384.4M · 12% of revenue COST OF REVENUE $384.4M 12% of revenue Operating profit: $1.5B · 47% margin OPERATING PROFIT $1.5B 47% margin · +8% Y/Y Other income: $221.4M · 7% of revenue OTHER INCOME $221.4M 7% of revenue Operating expenses: $1.3B · 41% of revenue OPERATING EXPENSES $1.3B 41% of revenue Net profit: $1.3B · 42% margin NET PROFIT $1.3B 42% margin · +12% Y/Y Tax: $379.2M · 12% of revenue TAX $379.2M 12% of revenue R&D: $550.0M · 17% of revenue R&D $550.0M 17% of revenue SG&A: $755.8M · 24% of revenue SG&A $755.8M 24% of revenue
Gross profit $2.8B 88% margin · +9% Y/Y
Operating profit $1.5B 47% margin · +8% Y/Y
Net profit $1.3B 42% margin · +12% Y/Y
The full income statement, year by year

UTHR among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 10.6%, above 51% of 154 peers (their median 10.4%) REVENUE GROWTH 10.6% · above 51% Gross margin: 86.3%, above 91% of 107 peers (their median 63.4%) GROSS MARGIN 86.3% · above 91% Operating margin: 41.4%, above 97% of 138 peers (their median 9.8%) OPERATING MARGIN 41.4% · above 97% Net margin: 38.6%, above 98% of 153 peers (their median 6.7%) NET MARGIN 38.6% · above 98% FCF margin: 27.2%, above 91% of 144 peers (their median 9.9%) FCF MARGIN 27.2% · above 91% Return on capital: 18.5%, above 85% of 89 peers (their median 9.0%) RETURN ON CAPITAL 18.5% · above 85%
UTHR Peer median Below the median

What changed

7 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 25, 2026 against Feb 26, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +25.4% ($279.3M to $350.2M) vs revenue +10.6% ($2.9B to $3.2B), +14.8 pts apart
  • Cash from operations $1.6B vs net income $1.3B (FY ending Dec 31, 2025)
9 more checks with nothing to note
  • Inventory +16.0% ($157.9M to $183.1M) vs revenue +10.6% ($2.9B to $3.2B), +5.3 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No longer listed: F-2 United Therapeutics, a public benefit corporation. Same as last year: Revenue Deductions — Accounting for Rebates; Our Audit
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

7 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.

All 7 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    Investing in our securities involves uncertainty and risk due to a variety of factors. You should carefully consider each of the following risks and all of the other information contained in this Report and in other documents that we file with, or furnish to, the SEC before making any investment decision with respect to our securities.…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    In April 2025, the Trump administration announced a reduction in force at the U.S. Department of Health and Human Services, including layoffs at the FDA. These and other efforts to reduce the size of the FDA or its funding, combined with changes in FDA leadership, have begun to result in slower FDA response times and/or longer review…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
    More recently, the One Big Beautiful Bill Act, which was enacted in July 2025, significantly reduced funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect our sales of our commercial products. The…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$1.9B$2.3B$2.9B$3.2B
Net income$727.3M$984.8M$1.2B$1.3B
Operating cash flow$802.5M$978.0M$1.3B$1.6B
Free cash flow$663.7M$747.6M$1.1B$1.0B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$3.2B ▲ 10.6% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

6 filings in the last 30 days · SEC EDGAR

All filings
1 more

About the company

UNITED THERAPEUTICS Corp, Silver Spring, MD · from the 10-K filed Feb 25, 2026

Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension (PAH), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies.

Headquarters
Silver Spring, MD
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 4, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we had approximately 1,400 employees working across our 15 locations worldwide" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/UTHR/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.